Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by canadafanon Aug 25, 2022 6:28pm
379 Views
Post# 34921171

in the evne there is a negotiated offer?!

in the evne there is a negotiated offer?!Please understand the process.
In the event there is a "negotiated" offer.
Meaning something with substance that would be accptable to the long term value of ONC
THAT, offer should first be vetted by the B.O.D. 
Assuinmg they also feel a good value opportunity,considering  all of the existing variables. then they would recomend.
That would trigger a shareholder offer & vote of accpetance or rejection.

Now! The important part of the equation is "what the comercial" value of Pelareorep is as a marketable drug.
The length of time ONC has been around, who is in charge , what you or anyone paid for the shares is 100% not important.
If/when a Pharma buys ONC, thier analysis will be this simple:
"what can Pela add to our bottom line"? and "what is the pay back time of our investment"
The actual vaule "cost" is not as important as the payback time & inherent risk.
The Price/share is not a consideration, ...only after the fact once a number is reached.
Right now, there is a certian risk built in, based on in-place trials & outcomes.
The assumption is. that Once things become mauch more clear ( Q4 of this year), many of the value risk questions will be answered. Then the "value" goes up.
My feelings? There are ,multiple discussions around various "offers"None fimed up yet.
When they become firm , we will hear & very fast.

<< Previous
Bullboard Posts
Next >>